Artificial intelligence (AI) for diagnostic purposes represents a potential technology breakthrough in medicine. Its diagnostic application within gastroenterology and hepatology conditions has grown quickly and robustly, with its first United States Food and Drug Administration authorization for use in 2021. As research funding and commercial development continue at a fast pace, the question of where AI-based diagnosis can have the biggest impact has not been sufficiently addressed. Although improvement in the diagnosis of any condition has benefits, there are also real costs associated with implementing AI-based solutions and opportunity costs associated with prioritizing funding and development decisions.
Keep Reading
Add A Comment